A
Accipiter Biosciences
AI-designed de novo protein therapeutics
About Accipiter Biosciences
Accipiter Biosciences is a Seattle-based biotechnology company that designs and develops de novo protein therapies using computational protein design. Its single-agent biologics are custom-engineered to engage multiple pathways in one molecule, avoiding the limits of traditional combination therapies, with a focus on immunology and oncology.
The company applies AI and in silico methods rooted in protein design research at the University of Washington to create fully customizable multifunctional proteins and can move from design to laboratory testing in under two months. It advances several internal drug programs toward clinical trials and has collaboration and license agreements with Pfizer and with Kite, a Gilead company, for engineered molecules and cell therapy applications.
Accipiter is a venture-backed drug developer that combines its own pipeline with milestone and royalty-bearing pharma partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Seattle, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 68.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Jul 2026 | $11M | $42M | Takeda Ventures · Columbus Venture Partners · Argonautic Ventures · Pack Ventures | ↗ |
| SEEDOther financing | Nov 2025 | $13M | $51M | Argonautic Ventures · Cercano Management · Columbus Venture Partners · Takeda Ventures | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
Takeda Ventures
Flying Fish Partners
Argonautic Ventures
Cercano Management
Columbus Venture Partners
Alexandria Venture Investments
Pack Ventures
Takeda
Other known investors1 additional known investor
University of Washington Institute for Protein Design
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Accipiter Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accipiter Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.